date,text,url,form,accepted_time
2020-01-24," 8-k 1 f8k012420_healthcare.htm current report united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): january 24, 2020 (january 24, 2020) healthcare merger corp. (exact name of registrant as specified in its charter) delaware 001-39160 83-1905538 (state or other jurisdiction of incorporation) (commission file number) (irs employer identification no.) 623 fifth avenue, 14th floor new york, ny 10022 (address of principal executive offices, including zip code) registrant’s telephone number, including area code: (646) 975-6581 not applicable (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ☐ soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ☐ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ☐ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered units, each consisting of one share of class a common stock and one-half of one redeemable warrant hccou the nasdaq stock market llc class a common stock, par value $0.0001 per share hcco the nasdaq stock market llc warrants, each exercisable for one share class a common stock for $11.50 per share hccow the nasdaq stock market llc indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 (§230.405 of this chapter) or rule 12b-2 of the securities exchange act of 1934 (§240.12b-2 of this chapter). emerging growth company þ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 8.01. other events. separate trading of units, class a common stock and warrants on january 24, 2020, healthcare merger corp. (the “company”) announced that, commencing on january 28, 2020, the holders of units issued in its initial public offering (the “units”), each consisting of one share of class a common stock of the company, par value $0.0001 per share (the “class a common stock”), and one half of one warrant of the company (“warrant”), with each whole warrant entitling the holder thereof to purchase one share of class a common stock for $11.50 per share, may elect to separately trade shares of class a common stock and warrants included in the units. no fractional warrants will be issued upon separation of the units and only whole warrants will trade. the units not separated will continue to trade on the nasdaq capital market under the symbol “hccou.” shares of class a common stock and the warrants are expected to trade on the nasdaq capital market under the symbols “hcco” and “hccow,” respectively. holders of units will need to have their brokers contact continental stock transfer & trust company, the company’s transfer agent, in order to separate the units into shares of class a common stock and warrants. item 9.01 financial statements and exhibits. (d) exhibits exhibit no. description 99.1 press release, dated january 24, 2020 signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. healthcare merger corp. by: /s/ dennis m. conroy name: dennis m. conroy title: chief financial officer dated: january 24, 2020 ",https://www.sec.gov/Archives/edgar/data/1791091/000121390020001743/0001213900-20-001743-index.htm,8-K,2020-01-24 16:15:26
2019-12-23," 8-k 1 f8k121719_healthcaremerger.htm current report united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): december 23, 2019 (december 17, 2019) healthcare merger corp. (exact name of registrant as specified in its charter) delaware 001-39160 84-3131208 (state or other jurisdiction of incorporation) (commission file number) (irs employer identification no.) 623 fifth avenue, 14th floor new york, ny 10022 (address of principal executive offices, including zip code) registrant’s telephone number, including area code: (646) 975-6581 not applicable (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ☐ soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ☐ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ☐ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered units, each consisting of one share of class a common stock and one-half of one redeemable warrant hccou the nasdaq stock market llc class a common stock, par value $0.0001 per share hcco the nasdaq stock market llc warrants, each exercisable for one share class a common stock for $11.50 per share hccow the nasdaq stock market llc indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 (§230.405 of this chapter) or rule 12b-2 of the securities exchange act of 1934 (§240.12b-2 of this chapter). emerging growth company þ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 8.01. other events. on december 17, 2019, healthcare merger corp. (the “company”) consummated its initial public offering (the “ipo”) of 25,000,000 units (the “units”), including 3,000,000 units issued pursuant to the exercise of the underwriters’ over-allotment option. each unit consists of one share of class a common stock of the company, par value $0.0001 per share (“class a common stock”) and one half of one redeemable warrant of the company (each whole warrant, a “warrant”), with each whole warrant entitling the holder thereof to purchase one share of class a common stock for $11.50 per share. the units were sold at a price of $10.00 per unit, generating gross proceeds to the company of $250,000,000. on december 17, 2019, simultaneously with the consummation of the ipo, the company completed the private sale (the “private placement”) of an aggregate of 700,000 units (the “private placement units”) to hcmc sponsor llc (the “sponsor”), generating gross proceeds to the company of $7,000,000. in addition, the 6,325,000 shares of class b common stock of the company (the “founder shares”) held by the sponsor (prior to the exercise of the over-allotment) included an aggregate of up to 825,000 founder shares subject to forfeiture by the sponsor to the extent that the underwriters’ over-allotment option was not exercised in full. since the underwriters exercised the over-allotment option in part, the sponsor forfeited 75,000 founder shares on december 17, 2019. the founder shares forfeited by the sponsor were cancelled by the company. a total of $250,000,000, comprised of $243,000,000 of the proceeds from the ipo (which amount includes $8,750,000 of the underwriters’ deferred discount) and $7,000,000 of the proceeds of the sale of the private placement units, was placed in a u.s.-based trust account at j.p. morgan chase bank, n.a., maintained by continental stock transfer & trust company, acting as trustee. an audited balance sheet as of december 17, 2019 reflecting receipt of the proceeds upon consummation of the ipo and the private placement has been issued by the company and is included as exhibit 99.1 to this current report on form 8-k. item 9.01. financial statements and exhibits. (d) exhibits exhibit no. description 99.1 audited balance sheet as of december 17, 2019. 1 signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. healthcare merger corp. date: december 23, 2019 by: /s/ dennis m. conroy name: dennis m. conroy title: chief financial officer 2 ",https://www.sec.gov/Archives/edgar/data/1791091/000121390019026840/0001213900-19-026840-index.htm,8-K,2019-12-23 16:30:27
2019-12-17," 8-k 1 f8k121219_healthcaremerger.htm current report united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of report (date of earliest event reported): december 17, 2019 (december 12, 2019) healthcare merger corp. (exact name of registrant as specified in its charter) delaware 001-39160 83-1905538 (state or other jurisdiction of incorporation) (commission file number) (irs employer identification no.) 623 fifth avenue, 14th floor new york, ny 10022 (address of principal executive offices, including zip code) registrant’s telephone number, including area code: (646) 975-6581 not applicable (former name or former address, if changed since last report) check the appropriate box below if the form 8-k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ written communications pursuant to rule 425 under the securities act (17 cfr 230.425) ☐ soliciting material pursuant to rule 14a-12 under the exchange act (17 cfr 240.14a-12) ☐ pre-commencement communications pursuant to rule 14d-2(b) under the exchange act (17 cfr 240.14d-2(b)) ☐ pre-commencement communications pursuant to rule 13e-4(c) under the exchange act (17 cfr 240.13e-4(c)) securities registered pursuant to section 12(b) of the act: title of each class trading symbol(s) name of each exchange on which registered units, each consisting of one share of class a common stock and one-half of one redeemable warrant hccou the nasdaq stock market llc class a common stock, par value $0.0001 per share hcco the nasdaq stock market llc redeemable warrants, each whole warrant exercisable for one share of class a common stock at an exercise price of $11.50 per share hccow the nasdaq stock market llc indicate by check mark whether the registrant is an emerging growth company as defined in rule 405 of the securities act of 1933 (§230.405 of this chapter) or rule 12b-2 of the securities exchange act of 1934 (§240.12b-2 of this chapter). emerging growth company þ if an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the exchange act. ☐ item 1.01. entry into a material definitive agreement. on december 16, 2019, healthcare merger corp. (the “company”) consummated its initial public offering (the “ipo”) of 25,000,000 units (the “units”), including 3,000,000 units issued pursuant to the partial exercise of the underwriter’s over-allotment option. each unit consists of one share of class a common stock of the company, par value $0.0001 per share (“class a common stock”), and one-half of one redeemable warrant of the company (“warrant”), with each whole warrant entitling the holder thereof to purchase one share of class a common stock for $11.50 per share. the units were sold at a price of $10.00 per unit, generating gross proceeds to the company of $250,000,000. in connection with the ipo, the company entered into the following agreements, forms of which were previously filed as exhibits to the company’s registration statement on form s-1 (file no. 333-235253) related to the ipo, originally filed with the u.s. securities and exchange commission (the “commission”) on november 25, 2019 (as amended, the “registration statement”): ● an underwriting agreement, dated december 12, 2019, by and between the company and cantor fitzgerald & co., as the sole underwriter, a copy of which is attached as exhibit 1.1 hereto and incorporated herein by reference. ● a warrant agreement, dated december 12, 2019, by and between the company and continental stock transfer & trust company, as warrant agent, a copy of which is attached as exhibit 4.1 hereto and incorporated herein by reference. ● a letter agreement, dated december 12, 2019, by and among the company, its officers, its directors and the company’s sponsor, hcmc sponsor llc (the “sponsor”), a copy of which is attached as exhibit 10.1 hereto and incorporated herein by reference. ● an investment management trust agreement, dated december 12, 2019, by and between the company and continental stock transfer & trust company, as trustee, a copy of which is attached as exhibit 10.2 hereto and incorporated herein by reference. ● a registration rights agreement, dated december 12, 2019, by and between the company and the sponsor, a copy of which is attached as exhibit 10.3 hereto and incorporated herein by reference. ● an administrative support agreement, dated december 12, 2019, by and between the company and mts health partners, l.p., an affiliate of the sponsor, a copy of which is attached as exhibit 10.4 hereto and incorporated herein by reference. ● a unit subscription agreement, dated december 12, 2019 (the “unit subscription agreement”), by and between the company and the sponsor, a copy of which is attached as exhibit 10.5 hereto and incorporated herein by reference. item 3.02. unregistered sales of equity securities. simultaneously with the closing of the ipo, pursuant to the unit subscription agreement, the company completed the private sale of an aggregate of 700,000 units (the “private placement units”) to the sponsor at a purchase price of $10.00 per private placement unit, generating gross proceeds to the company of $7,000,000. the private placement units (and the underlying securities) are identical to the units sold as part of the units in the ipo, except as otherwise disclosed in the registration statement. no underwriting discounts or commissions were paid with respect to such sale. the issuance of the private placement units was made pursuant to the exemption from registration contained in section 4(a)(2) of the securities act of 1933, as amended. 1 item 5.03. amendments to certificate of incorporation or bylaws; change in fiscal year. on december 12, 2019, in connection with the ipo, the company filed its amended and restated certificate of incorporation with the secretary of state of the state of delaware, effective the same day. the terms of the amended and restated certificate of incorporation are set forth in the registration statement and are incorporated herein by reference. a copy of the amended and restated certificate of incorporation is attached as exhibit 3.1 hereto and incorporated herein by reference. item 8.01. other events. a total of $250,000,000, comprised of $243,000,000 of the proceeds from the ipo (which amount includes $8,750,000 of the underwriter’s deferred discount) and $7,000,000 of the proceeds of the sale of the private placement units, was placed in a u.s.-based trust account at j.p. morgan chase bank, n.a., maintained by continental stock transfer & trust company, acting as trustee. except with respect to interest earned on the funds held in the trust account that may be released to the company to pay its taxes (less up to $100,000 interest to pay dissolution expenses), the funds held in the trust account will not be released from the trust account until the earliest of (i) the completion of the company’s initial business combination, (ii) the redemption of any of the company’s public shares properly submitted in connection with a stockholder vote to amend the company’s amended and restated certificate of incorporation (a) to modify the substance or timing of its obligation to redeem 100% of the company’s public shares if it does not complete its initial business combination within 24 months from the closing of the ipo or (b) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity and (iii) the redemption of the company’s public shares if it is unable to complete its initial business combination within 24 months from the closing of the ipo, subject to applicable law. in addition, the 6,325,000 shares of class b common stock of the company (the “founder shares”) held by the sponsor (prior to the exercise of the over-allotment) included an aggregate of up to 825,000 founder shares subject to forfeiture by the sponsor to the extent that the underwriters’ over-allotment option was not exercised in full. since the underwriters exercised the over-allotment option in part, the sponsor forfeited 75,000 founder shares on december 17, 2019. the founder shares forfeited by the sponsor were cancelled by the company. on december 12, 2019, the company issued a press release announcing the pricing of the ipo, a copy of which is attached as exhibit 99.1 to this current report on form 8-k. on december 17, 2019, the company issued a press release announcing the closing of the ipo, a copy of which is attached as exhibit 99.2 to this current report on form 8-k. item 9.01 financial statements and exhibits. (d) exhibits the following exhibits are being filed herewith: exhibit no. description 1.1 underwriting agreement, dated december 12, 2019, by and between the company and cantor fitzgerald & co., as the sole underwriter. 3.1 amended and restated certificate of incorporation. 4.1 warrant agreement, dated december 12, 2019, by and between the company and continental stock transfer & trust company, as warrant agent. 10.1 letter agreement, dated december 12, 2019, by and among the company, its officers, its directors and the sponsor. 10.2 investment management trust agreement, dated december 12, 2019, by and between the company and continental stock transfer & trust company, as trustee. 10.3 registration rights agreement, dated december 12, 2019, by and between the company and sponsor. 10.4 administrative support agreement, dated december 12, 2019, by and between the company and mts health partners, l.p., an affiliate of hcmc sponsor llc. 10.5 unit subscription agreement, dated december 12, 2019, by and between the company and the sponsor. 99.1 press release, dated december 12, 2019. 99.2 press release, dated december 17, 2019. 2 signature pursuant to the requirements of the securities exchange act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. healthcare merger corp. by: /s/ dennis m. conroy name: dennis m. conroy title: chief financial officer dated: december 17, 2019 3 ",https://www.sec.gov/Archives/edgar/data/1791091/000121390019026339/0001213900-19-026339-index.htm,8-K,2019-12-17 16:16:05
